Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Feng Zhang
Broad Institute, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Editas Medicine
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Company Editas Medicine has licensed the genomic editing technology invented by Feng Zhang to translate it into a novel class of human therapeutics. The genome editing technology was partially developed by and is a fundamental component of the ongoing research of the PI's lab.
Dr. Zhang plays an integral role in the scientific direction of the company. He along with the founders is one of ten senior participants in the company and sets scientific direction. He will be involved in the selection of the new Chief Scientific Officer and will meet and interview the Chief Executive Officer. That said, he is NOT on the Board of Directors, will not vote on the selection of either the CSO or CEO and does not exercise any fiduciary responsibility for Editas.
Probing Neuropsychiatric Diseases Using Targeted Epigenome and Genome Engineering
Major depressive disorder is a devastating mental illness affecting millions of Americans annually, with a large fraction of patients unresponsive to available therapies. The proposed project aims to identify fundamentally new classes of therapeutics by probing the epigenetic mechanisms contributing to major depression, through a combination of innovative technology development, and systematically establishing causal links between epigenetic targets and disease phenotype. The technologies developed through this proposal will establish a new epigenetic paradigm for drug discovery and have broad impacts for many fields of biomedical research including cancer, diabetes, obesity, and other neurological disorders.
Filed on February 13, 2014.
Tell us what you know about Feng Zhang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.